Treatment of cold tumors with some inhibitors such as Vps34 inhibitors can induce the release of inflammatory chemokines such as CCL5 and CXCL10 to recruit natural killer (NK) and CD8+ T cells to the tumor microenvironment, resulting in a better immunotherapeutic efficacy [16]. The gene discussed is CXCL10; the disease is neoplasm.